{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000131","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.251010+00:00","generated_at":"2026-06-14T06:42:19.345454+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC","bullets":["RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.","Confirmed ORR 36.8% (7/19) in ovarian/USC with intermittent dosing vs 19.2% (5/26) continuous.","No discontinuations due to TRAEs in intermittent cohorts; improved tolerability over continuous dosing.","Three Phase 2 monotherapy trials enrolling: Cyclin E1+ ovarian, USC, PARPi-resistant ovarian cancer.","Company plans H2 2023 update on Phase 1 dose optimization data and Phase 2 program timelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000131","json":"https://secwatch.observer/filing/0001725160-23-000131.json","markdown":"https://secwatch.observer/filing/0001725160-23-000131.md","text":"https://secwatch.observer/filing/0001725160-23-000131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/0001725160-23-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/zntl-20230606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:42:19.345454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}